UCB : Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa -October 12, 2023 at 12:03 pm EDT

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa




Bimekizumab...

Related Keywords

Germany ,Belgium ,Berlin ,Brussels ,Bruxelles Capitale ,J Clin Pharmacol ,Hidradenitis Suppurativa ,Klinikum Dessau ,Laurent Schots ,Eimear Obrien ,Emmanuel Caeymaex ,Antje Witte ,Brand Communications ,European Union ,International Hidradenitis Suppurativa Severity Score System ,Immunology Solutions ,Corporate Communications ,Twitter ,European Hidradenitis Suppurativa Foundation ,Brandenburg Medical School ,European Academy Of Dermatology ,Executive Vice President ,Professor Christos ,Founding Professor ,Important Safety ,Euronext Brussels ,Study Participants With Moderate ,Severe Hidradenitis Suppurativa ,Rev Dis ,Clin Cosmet Investig ,Its Effect ,Markets ,